Rice Hall James & Associates LLC Grows Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Rice Hall James & Associates LLC increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 14.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,482 shares of the medical device company’s stock after buying an additional 13,224 shares during the period. Rice Hall James & Associates LLC’s holdings in Tandem Diabetes Care were worth $3,799,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brooklyn Investment Group purchased a new stake in Tandem Diabetes Care during the 3rd quarter worth $28,000. Assetmark Inc. purchased a new stake in Tandem Diabetes Care during the 3rd quarter worth $29,000. Waldron Private Wealth LLC bought a new stake in shares of Tandem Diabetes Care in the 3rd quarter worth about $50,000. McIlrath & Eck LLC bought a new stake in shares of Tandem Diabetes Care in the 3rd quarter worth about $52,000. Finally, Venturi Wealth Management LLC increased its position in shares of Tandem Diabetes Care by 5,955.9% in the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock worth $74,000 after purchasing an additional 2,025 shares during the last quarter.

Tandem Diabetes Care Stock Down 2.5 %

Tandem Diabetes Care stock opened at $32.62 on Wednesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The firm has a 50-day moving average price of $35.63 and a two-hundred day moving average price of $36.95. Tandem Diabetes Care, Inc. has a 52-week low of $22.03 and a 52-week high of $53.69.

Analysts Set New Price Targets

TNDM has been the subject of several research analyst reports. Citigroup dropped their target price on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 target price for the company. Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price for the company in a research report on Monday, December 2nd. Barclays boosted their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Robert W. Baird dropped their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research report on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.